QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inflammation and Neurodegeneration Research

Executive Summary: QNZ (EVP4593) is a quinazoline derivative NF-κB inhibitor with an IC₅₀ of 11 nM in Jurkat T cells, acting through direct inhibition of NF-κB transcriptional activation (APExBIO product page). It effectively blocks PMA/PHA-induced NF-κB activation and TNF-α production at sub-10 nM concentrations (APExBIO, 2024). QNZ demonstrates significant anti-inflammatory activity in vivo by suppressing edema formation in a rat model (Yang et al., 2025). Its solubility profile (≥10.06 mg/mL in ethanol, ≥15.05 mg/mL in DMSO) and stability parameters enable robust experimental integration. QNZ is a validated tool for studying NF-κB pathway modulation, inflammation, and neurodegenerative disease models, including Huntington’s disease (see application summary).

Biological Rationale

The NF-κB family of transcription factors orchestrates immune, inflammatory, and stress responses. Aberrant NF-κB activation is implicated in chronic inflammation, autoimmunity, cancer, and neurodegeneration. In skeletal infections such as osteomyelitis, persistent inflammation impairs effective bacterial clearance and contributes to tissue damage (Yang et al., 2025). Therapeutic modulation of NF-κB activity is a validated strategy for attenuating excessive inflammatory signaling and mitigating disease progression. QNZ (EVP4593) targets this central node with high selectivity and potency, providing researchers with a reproducible tool for dissecting NF-κB's role in health and disease.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a quinazoline derivative identified via luciferase reporter assays for NF-κB transcriptional activity (APExBIO). It inhibits NF-κB signaling by preventing phosphorylation and degradation of IκBα, thereby blocking the nuclear translocation of NF-κB subunits. This leads to suppression of downstream inflammatory mediators, including TNF-α and other cytokines. In neuronal cultures, QNZ at 300 nM reduces store-operated calcium entry (SOC), a process relevant to Huntington’s disease pathology (see disease model application). The compound does not exhibit direct cytotoxicity at effective concentrations in preclinical models. QNZ’s selectivity for NF-κB and its downstream gene targets enables precise modulation of inflammatory and immune responses.

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB transcriptional activation in human Jurkat T cells with an IC₅₀ of 11 nM under standardized luciferase reporter conditions (APExBIO).
• PMA/PHA-induced TNF-α production is blocked by QNZ with an IC₅₀ of 7 nM in cell-based assays (APExBIO).
• QNZ demonstrates in vivo anti-inflammatory efficacy by reducing carrageenin-induced paw edema in rats (protocol: acute inflammation, single-dose, intraperitoneal administration) (Yang et al., 2025).
• In Drosophila Huntington’s disease models, QNZ slows progressive motor decline and does not cause toxicity at active doses (HD application summary).
• QNZ is insoluble in water but achieves ≥10.06 mg/mL in ethanol (with ultrasonic assistance) and ≥15.05 mg/mL in DMSO (APExBIO, 2024).

Applications, Limits & Misconceptions

QNZ (EVP4593) is widely used to study:

• NF-κB pathway modulation in immune, inflammatory, and cancer models.
• Anti-inflammatory mechanisms in acute and chronic disease models.
• Neurodegenerative disease processes, notably Huntington’s disease.
• Store-operated calcium entry (SOC) inhibition in neuronal cultures.

This article extends previous overviews (QNZ (EVP4593): Reliable NF-κB Inhibition for Reproducible...), by providing detailed atomic benchmarks for specific experimental systems and clarifying optimal solubility/stability conditions overlooked in earlier summaries.

Common Pitfalls or Misconceptions

• QNZ is not water-soluble; attempting to dissolve it directly into aqueous buffers will result in precipitation and unreliable dosing.
• The compound is not recommended for long-term storage in solution; aliquot and store stock at -20°C for best stability.
• QNZ does not directly target bacterial pathogens; its effect in infection models is mediated by host NF-κB pathway inhibition.
• NF-κB-independent inflammatory pathways (e.g., inflammasome-mediated responses) are not blocked by QNZ.
• High concentrations above 10 μM may induce off-target effects not related to NF-κB inhibition.

Workflow Integration & Parameters

QNZ (EVP4593) is supplied as a small molecule (molecular weight: 356.42, formula: C₂₂H₂₀N₄O) by APExBIO (SKU: A4217). For laboratory use:

• Solubilize in DMSO (≥15.05 mg/mL) or ethanol (≥10.06 mg/mL) using ultrasonic shaking and warming (37°C recommended).
• Prepare working dilutions freshly; avoid extended storage of diluted solutions.
• For neuronal SOC inhibition, use 300 nM in culture medium (application note).
• For in vivo anti-inflammatory studies, match dosing conditions (species, route, vehicle) to literature precedents for reproducibility.

For a practical strategies overview, see QNZ (EVP4593): Practical Strategies for Reliable NF-κB In..., which addresses workflow adaptations in cell-based and in vivo assays. This article updates those recommendations with new solubility and application data.

Conclusion & Outlook

QNZ (EVP4593) is a benchmark quinazoline NF-κB inhibitor enabling precise, reproducible modulation of inflammatory and neurodegenerative processes (APExBIO). Its validated potency, favorable solubility parameters, and translational performance in vivo recommend it for mechanistic studies and drug discovery. Future research may expand its applications to combinatorial therapies and further clarify its selectivity profile in complex disease contexts. For robust experimental results, strict adherence to solubility and dosing guidance is essential.

For additional translational insights, see QNZ (EVP4593): Potent NF-κB Inhibitor for Translational R..., which emphasizes clinical relevance; this article focuses on atomic performance benchmarks and integration tips.